Application of medicine for inhibiting SARS-CoV-2 virus replication and kit

A virus replication, sars-cov-2 technology, applied in the field of drug use and kits, can solve problems such as limited therapeutic effect of anti-SARS-CoV-2 virus drugs

Inactive Publication Date: 2021-04-20
山东君立生物医药有限公司
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Through the above analysis, the existing problems and defects of the prior art are: the therapeutic effect of existing anti-SARS-CoV-2 virus drugs is relatively limited

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of medicine for inhibiting SARS-CoV-2 virus replication and kit
  • Application of medicine for inhibiting SARS-CoV-2 virus replication and kit
  • Application of medicine for inhibiting SARS-CoV-2 virus replication and kit

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] The use of the present invention in the preparation of a medicament for inhibiting the replication of the SARS-CoV-2 virus with a content of 100% by mass.

[0037] Use of the challelic acid in the preparation of novel SARS-CoV-2 inhibitors.

[0038] The present invention provides a target cell for expressing the novel SARS-CoV-2 inhibitor in the use to inhibit the replication of SARS-CoV-2.

[0039] The present invention provides a kit for detecting SARS-CoV-2 viral replication inhibition ability, said kit comprising the said use of charexed acid, and said target cells.

[0040] The invention provides a method of inhibiting 3-chymotrypsin-like cysteine ​​protease 3CL in the preparation of challek acid in the use Pro Active Pharmaceutical Uses.

[0041]The preparation inhibits 3-chymotrypsin-like cysteine ​​protease 3CL Pro Active drug, including anti-3-chymotrypsin-like cysteine ​​protease 3CL Pro Screening for inhibitory effects of activity:

[0042] Purified SARS...

Embodiment 2

[0046] The use of punicalagin in the present invention in the preparation of a drug for inhibiting the replication of SARS-CoV-2 virus with a content of 100% by mass.

[0047] The use of the punicalagin in any combination in the preparation of novel SARS-CoV-2 inhibitors.

[0048] The present invention provides a target cell for expressing the novel SARS-CoV-2 inhibitor in the use to inhibit the replication of SARS-CoV-2.

[0049] The present invention provides a kit for detecting SARS-CoV-2 viral replication inhibition ability, said kit comprising said punicalagin in use, and said target cell.

[0050] The present invention provides a kind of said punicalagin in the preparation of inhibiting 3-chymotrypsin-like cysteine ​​protease 3CL Pro Active Pharmaceutical Uses.

[0051] The preparation inhibits 3-chymotrypsin-like cysteine ​​protease 3CL Pro Active drug, including anti-3-chymotrypsin-like cysteine ​​protease 3CL Pro Screening for inhibitory effects of activity:

[0...

Embodiment 3

[0056] The present invention provides a combination of chevalacid and punicalagin in any proportion in the preparation of a medicine for inhibiting the replication of SARS-CoV-2 virus.

[0057] The use of the combination of chevalacid and punicalagin in any ratio in the preparation of novel SARS-CoV-2 inhibitors.

[0058] The present invention provides a target cell for expressing the novel SARS-CoV-2 inhibitor in the use to inhibit the replication of SARS-CoV-2.

[0059] The present invention provides a test kit for detecting the ability of SARS-CoV-2 virus replication inhibition, the test kit comprises the composition of cherelic acid and punicalagin in any ratio in the use, and the target cell.

[0060] The present invention provides a method of inhibiting 3-chymotrypsin-like cysteine ​​protease 3CL in the preparation of the combination of cherelic acid and punicalagin in any ratio in the use. Pro Active Pharmaceutical Uses.

[0061] The preparation inhibits 3-chymotryps...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the technical field of biological pharmacy, and discloses an application of a medicine for inhibiting SARS-CoV-2 virus replication and an application of combination of chebulagic acid and punicalagin in any proportion in preparation of the medicine for inhibiting SARS-CoV-2 virus replication. Experiments for inhibition capacity of two broad-spectrum antiviral natural products, namely chebulagic acid and punicalagin, on SARS-CoV-2 virus replication show that chebulagic acid and punicalagin can be used as novel SARS-CoV-2 inhibitors; and under non-cytotoxic concentrations, chebulagic acid and punicalagin reduce the formation of virus-induced VERO-E6 cell monolayer plaques in a reversible and non-competitive manner by targeting the enzymatic activity of viral 3CLPro (3-chymotrypsin-like cysteine protease), and have potential application as the novel COVID-19 therapy.

Description

technical field [0001] The invention belongs to the technical field of biopharmaceuticals, and in particular relates to a use and a kit of a medicine for inhibiting SARS-CoV-2 virus replication. Background technique [0002] Currently, novel coronavirus pneumonia (COVID-19) is an pneumonia disease caused by severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2). However, so far, no specific antiviral therapy is available for clinical use. Although many potentially effective in vitro antiviral drugs, such as remdesivir and chloroquine, can inhibit SARS-CoV-2 replication, chloroquine proved ineffective in clinical trials. Remdesivir has been approved for emergency use in many countries, but its therapeutic effect is relatively limited. Therefore, there is an urgent need to discover effective anti-SARS-CoV-2 viral drugs for use alone or in combination with approved antiviral therapies to combat the COVID-19 outbreak. [0003] Through the above analysis, the existi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/7048A61P31/14C12Q1/70C12Q1/02C12Q1/37C12R1/93
Inventor 杜瑞坤崔清华荣立军
Owner 山东君立生物医药有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap